Mind Medicine (MindMed), Inc. (MNMD)

NASDAQ: MNMD · IEX Real-Time Price · USD
2.78
+0.01 (0.36%)
At close: Nov 25, 2022 1:00 PM
2.83
+0.05 (1.80%)
After-hours: Nov 25, 2022 4:41 PM EST
0.36%
Market Cap 104.07M
Revenue (ttm) n/a
Net Income (ttm) -70.64M
Shares Out 29.30M
EPS (ttm) -0.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Aug 29, 2022
Volume 166,552
Open 2.8
Previous Close 2.77
Day's Range 2.72 - 2.83
52-Week Range 2.35 - 32.25
Beta 2.15
Analysts Buy
Price Target 45.90 (+1,551.1%)
Earnings Date Nov 10, 2022

About MNMD

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3... [Read more]

Industry Biotechnology
Founded 2019
CEO Robert Barrow
Employees 41
Stock Exchange NASDAQ
Ticker Symbol MNMD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for MNMD stock is "Buy." The 12-month stock price forecast is 45.9, which is an increase of 1,551.08% from the latest price.

Price Target
$45.9
(1,551.08% upside)
Analyst Consensus: Buy
Stock Forecasts

News

MindMed to Participate in the Jefferies London Healthcare Conference

NEW YORK , Nov. 11, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to t...

2 weeks ago - PRNewsWire

MindMed Reports Third Quarter 2022 Financial Results and Business Highlights

– Initiated Phase 2b dose-optimization trial in patients with Generalized Anxiety Disorder, with first patients dosed in Q3 2022 and key clinical readout expected in late 2023 – – Advanced IND-enabling ...

2 weeks ago - PRNewsWire

MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial Results and Provide Business Update

NEW YORK , Nov. 3, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to tr...

3 weeks ago - PRNewsWire

7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov.

Risk is part of investing. Even the most mature, well-established firms and stocks run the risk of declining to zero.

4 weeks ago - InvestorPlace

Mind Medicine (MNMD) to Report Q3 Earnings: What's in Store?

Mind Medicine MindMed (MNMD) is expected to provide an update on its pipeline candidates in its third-quarter earnings.

4 weeks ago - Zacks Investment Research

Why Mind Medicine Zoomed 8% Higher on Tuesday

The support for legalizing drugs -- such as those being studied by the company -- grows with a U.S. senator's tweet.

1 month ago - The Motley Fool

MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference

NEW YORK , Oct. 5, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to tr...

1 month ago - PRNewsWire

Why Mind Medicine Stock Triumphed on Tuesday

The company is going back into the lab, and investors are eager to see what it discovers.

1 month ago - The Motley Fool

MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA

- Study will compare the acute subjective, physiological, and endocrine effects of R-MDMA, S-MDMA, and racemic MDMA in 24 healthy subjects - NEW YORK , Oct. 4, 2022 /PRNewswire/ -- Mind Medicine (MindMe...

1 month ago - PRNewsWire

Why Mind Medicine Stock Soared on a Down Day for the Market

A highly dilutive new round of financing is making the stock behave like a yo-yo.

1 month ago - The Motley Fool

MindMed Board is Trippin': Significant Investor Calls for Termination of Highly Dilutive Equity Offering and Pledges ...

Investors States Shareholder Requisition of Special Meeting to Effect Significant Change to the Board May be Necessary SHERIDAN, Wyo. , Sept. 28, 2022 /PRNewswire/ -- Today, FCM MM HOLDINGS, LLC ("FCM")...

1 month ago - PRNewsWire

Stock of psychedelics company MindMed slides 50% after it sells fresh shares

Shares of psychedelics company Mind Medicine Inc. slid 50% Wednesday, after the company priced a dilutive secondary offering of 7.1 million shares.

1 month ago - Market Watch

Why Mind Medicine (MindMed) Stock Is Crashing Today

The maker of psychedelic drugs announced the pricing of its latest public offering.

1 month ago - The Motley Fool

Why Is MindMed (MNMD) Stock Plunging 51% Today?

MindMed (NASDAQ: MNMD ) stock is plunging 51% today after the drug maker announced yesterday shortly before the market closed that it would sell an undisclosed number of common shares of MMED stock, alo...

1 month ago - InvestorPlace

Psychedelics company MindMed's shares slide 36% premarket as it prices dilutive 7.1 million share secondary offering

Shares of psychedelics company Mind Medicine Inc. MNMD, +6.43% slid 35.6% in premarket trade Wednesday, after the company priced a dilutive secondary offering of 7.1 million shares. The offering priced ...

1 month ago - Market Watch

MindMed Announces Pricing of Public Offering of Common Shares and Warrants

NEW YORK , Sept. 27, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed") (NASDAQ: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health ...

1 month ago - PRNewsWire

Stocks moving after hours: Big Bank stocks, Meta, MindMed

Yahoo Finance's Seana Smith breaks down major stock moves after the closing bell.

Other symbols: BACCGSMETAMS
1 month ago - Yahoo Finance

MindMed Announces Proposed Public Offering of Common Shares

NEW YORK , Sept. 27, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed") (Nasdaq: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health ...

1 month ago - PRNewsWire

MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

First-in-human trial to investigate the tolerability, pharmacology, and pharmacokinetics of novel MDMA-like compounds versus a placebo in healthy subjects Acute effects of equivalent doses will be compa...

2 months ago - PRNewsWire

Wall Street Says This Stock Can Deliver a 543% Return. Should You Listen?

Find out why investment bank analysts think this stock is positioned for a six-fold gain.

2 months ago - The Motley Fool

MindMed (MNMD) Stock Regains Nasdaq Compliance

Source: Daniel Patrick Martin / Shutterstock.com MindMed (NASDAQ: MNMD ) stock is in the news Wednesday after the psychedelic medicine company regained Nasdaq compliance. According to a press release fr...

2 months ago - InvestorPlace

MindMed Announces Compliance with Nasdaq Listing Requirements

NEW YORK , Sept. 14, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to ...

2 months ago - PRNewsWire

Why Mind Medicine (MindMed) Stock Tumbled This Week

MindMed's stock has been moving lower ever since its reverse split last month.

2 months ago - The Motley Fool

MindMed (MNMD) Stock Is Up on Psychedelics News

Source: Daniel Patrick Martin / Shutterstock.com MindMed (NASDAQ: MNMD ) stock is on the move Wednesday following positive data from a Phase II clinical trial of MM-120. MM-120 is an LSD treatment in de...

2 months ago - InvestorPlace

This Meme Stock Just Did a Huge Reverse Stock Split

Is Mind Medicine a buy?

2 months ago - The Motley Fool